Custom Fluorescence Imaging System Exploiting Hyperspectral Camera to Characterize and Diagnose RNA Breast Cancer

Early diagnosis of breast malignancy is a challenging task to permit this cancer. RNA offers incredible potential as a biomarker for malignant growth because of its noteworthy blood dependability and characteristic articulation in various diseases. We explored the total RNA to select the optimum spectral signature concerning entire blood that could segregate between liver cancer (HCC), early breast cancer growth, and normal persons. A custom Hyperspectral Imaging (HSI) system comprises a hyperspectral camera that works in wavelength (380~1050 nm) with ultraviolet (UV) source light (20 mW, 395 nm). It is associated with the custom software system to measure the total RNA signature of (n=50) subjects (n= 10 HCC patients, n= 15 breast cancer, and n=25 normal persons as a control). The experimental result shows that the scattering absorption of all the investigated samples is high at 395 nm based on (size, shape, medical state). Breast cancer RNA demonstrates fluorescence emission at 431 nm and 493 nm and Phosphorescence at 768 nm compared to the normal and HCC patients. Verifying the experimental results with the RNA cuvette spectral images shows that we could discriminate the HCC from the normal total RNA at 431 nm and the breast cancer from both normal and HCC at 768 nm. This prospective investigation shows that the mutation of the total RNA regarding certain diseases affecting its spectral signature exhibits potential detection of breast tumor and HCC in tissues using extracted RNA from Blood in advance and subsequently surgery in subjects with initial-stage breast cancer. A wavelength of 431 nm was optimum for discrimination between the HCC and the normal total RNA, and a wavelength of 768 nm was ideal for breast cancer discrimination.